AASLD: Once-Daily HCV Protease Inhibitors Show Early Promise

www.medpagetoday.com BOSTON -- Two investigational drugs targeting the hepatitis C virus (HCV) protease enzyme helped patients clear the virus with once-daily dosing, in contrast with the three-times-per-day schedule needed for similar drugs in development. ... medicine health
Author: MedPageToday; Tags: medicine health


















